Cystic FibrosisPhase 2NCT02740868
Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease
A Phase 2 study testing Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging and Lung Clearance Index in people with Cystic Fibrosis and Asthma, run by The Hospital for Sick Children at 1 site in Canada.
Trial summary
Aim of this study is to evaluate image quality and reproducibility of Xenon-129 and Inert fluorinated (19F) gas Magnetic Resonance Imaging (MRI) and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls. Read more about this study
- Who is it for?
- Ages 8 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cystic Fibrosis, Asthma
- What is being tested?
- Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging and Lung Clearance Index
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteCanada
- Study dates
- Aug 2015to 31 Dec 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Participants male and female aged 8 years old and older.
- Participants have no smoking history.
- For participants with CF and asthma, a clinical diagnosis is necessary and they should be at their baseline level of symptom control based on history.
- Participants should have a FEV1%pred value greater than 40%.
- Participant understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent or assent.
- Participant must be able to perform a breath hold for 20s or less.
- Participant able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater).
- For the PEx sub-cohort, admission to the Hospital for Sick Children for a pulmonary exacerbation (based on clinical or pulmonary function assessment). Children who will be admitted and then discharged on home IV antibiotics may also be included in this study.
Who cannot join
- Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent/assent from being obtained, or cannot read or understand the written material.
- Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension.
- Other than for the PEx sub-cohort, participant has had a cold or respiratory infection in the last four weeks.
- Participant requires supplemental oxygen or has a daytime room air oxygen saturation ≤ 95%.
- Participant is unable to perform spirometry or plethysmography maneuvers.
- Participant is pregnant or lactating.
Show all 9Show fewer
- In the investigator's opinion, participant suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
- Participant has an MRI incompatible device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bio prosthetic, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants).
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8
Giles Santyr, PhD FCCPM
About this study
Official title: Development of Hyperpolarized Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease
Aim of this study is to evaluate image quality and reproducibility of Xenon-129 and Inert fluorinated (19F) gas Magnetic Resonance Imaging (MRI) and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.
Read the detailed description
Hyperpolarized noble gas magnetic resonance (MR) lung imaging is a relatively new imaging method that allows depiction of both lung function and morphology. Hyperpolarized gases are a new class of MR contrast agent which, when inhaled, provide high temporal and spatial resolution MR images of the lung airspaces. Since no ionizing radiation is involved, hyperpolarized gas MR imaging is ideal for the evaluation of lung diseases especially in children. With hyperpolarized gases, the nuclear spins of the gas atoms are brought into alignment outside of the MR scanner via a process called optical pumping; this yields high polarizations and permits visualization of the lung airspaces with MR imaging (despite the low physical density of the gas in the lung). Two non-radioactive (i.e. stable) isotopes of noble gases helium-3 and xenon-129 can be hyperpolarized. Until recently, higher polarizations could be achieved with helium-3 than with xenon-129, so in humans, helium-3 was more commonly used for hyperpolarized gas MR imaging of the lungs. Recently, the technology has been developed to provide large quantities of highly polarized xenon-129. Helium-3 gas is also extremely expensive and since there are limited reserves of the gas, difficult to procure for research. Unlike helium-3, since xenon-129 is naturally present in the atmosphere, it is less expensive and easier to procure for imaging.
Several applications of xenon-129 MR imaging are under development, including diffusion-weighted and relaxation-weighted imaging. These techniques take advantage of the fact that the rate of loss of xenon-129 polarization is significantly influenced by the local blood flow and concentration of molecular oxygen, as well as the restriction of xenon-129 diffusion by small airway space dimensions. These data can be used to create maps of the lung reflecting regional ventilation/perfusion and micro-airway sizes. Other data that can be obtained with xenon-129 MRI include the volumes of ventilated and unventilated lungs which can subsequently be analyzed to determine the homogeneity of gas distribution within the airspaces. These data can be used to study the structural and functional changes taking place in the lungs associated with pulmonary diseases like CF and asthma. It might provide a diagnostic tool that is able to detect pulmonary diseases more sensitively than the current gold standard measurements of spirometry and plethysmography, and thus prevent irreparable and irreversible damage to the lungs in the early stages of disease.
19F MRI is an emergent technology for the imaging of lung ventilation and function. Similar to HP 129Xe MRI, this technique involves the imaging of an inhaled tracer (inert fluorinated gases) to visualize the airspaces of the lungs. Fluorinated gases such as perfluoropropane have been approved for use as an investigational inhaled contrast at several institutions globally, including a Canadian institution in Thunder Bay, Ontario. Fluorinated gases are non-toxic, commercially available, relatively inexpensive, and have favourable physical/magnetic properties for MRI17-20. Most importantly, unlike 129Xe MRI, fluorinated gases do not require hyperpolarization prior to imaging to boost detectable signal, instead relying on a relatively high number of 19F atoms per molecule and rapid, repeated imaging to enable sufficient signal averaging3. This is a significant advantage compared to HP 129Xe MRI which requires special polarizing equipment; a major barrier to widespread implementation. Despite this, the achievable image quality is generally poorer than 129Xe MRI. Nevertheless, recent improvements in hardware, software and fluorinated gases may enable 19F MRI to provide similar and/or complimentary information compared to HP 129Xe MRI at lower cost and with reduced requirements for hardware and infrastructure21.
Additionally, the paramagnetism of molecular oxygen (O2), which detrimentally impacts the hyperpolarization of 129Xe, does not significantly impact inert fluorinated gases. Therefore, these gases may be prepared in normoxic mixtures prior to administration to participants, rather than in anoxic mixtures as is typically done with 129Xe. This, alongside the fact that irreversible loss of magnetization is not a concern with fluorinated gases, presents the opportunity to perform free-breathing, extended imaging of the lungs. Imaging data acquired during free-breathing can potentially resolve gas kinetics (i.e., gas-wash-in, wash-out, and fractional ventilation)22,23 in a manner that is more feasible and tolerable than with HP noble gases.
Due to the lack of studies evaluating 19F MRI in pediatric lung disease, in this study we aim to develop and test necessary hardware/software for 19F MRI of the lungs children with and without history of respiratory disease and compare to HP 129Xe MRI.
- Conditions
- Cystic Fibrosis, Asthma
- Being tested
- Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging, Lung Clearance Index
- Keywords
- Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy
- Medical subject headings
- Cystic Fibrosis, Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Xenon-129 and Perfluoropropane (19F)Drug
Also called 129Xe and 19F
Xenon gas and perfluoropropane to be inhaled by research participants
Magnetic Resonance ImagingDevice
Also called MRI
Lung imaging will be performed for participants using MRI for all 3 arms
Lung Clearance IndexDevice
Also called LCI
Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
| Study group | Role | What they receive |
|---|---|---|
| Healthy | Active comparator | Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index. Receives: Drug: Xenon-129 and Perfluoropropane (19F); Device: Magnetic Resonance Imaging; Device: Lung Clearance Index |
| Cystic Fibrisos | Active comparator | Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index. Receives: Drug: Xenon-129 and Perfluoropropane (19F); Device: Magnetic Resonance Imaging; Device: Lung Clearance Index |
| Asthma | Active comparator | Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index. Receives: Drug: Xenon-129 and Perfluoropropane (19F); Device: Magnetic Resonance Imaging; Device: Lung Clearance Index |
What is being measured
The primary outcome is the main question the study is designed to answer.
Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement
To evaluate image quality and reproducibility of 129Xe and inert fluorinated (19F) gas MRI and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2016 (estimated)
- Study startAug 2015
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cystic FibrosisStudies of the same condition, open and under way.
- More trials run by The Hospital for Sick ChildrenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Hospital for Sick Children
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Giles Santyr, The Hospital for Sick Children
- Investigators
- Giles Santyr, PhD, Principal investigator, The Hospital for Sick Children
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02740868
- Sponsor's protocol ID
- 1000048243
- Status last verified
- Feb 2026
- First submitted
- 19 Aug 2015
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Munidasa S, Couch MJ, Rayment JH, Voskrebenzev A, Seethamraju R, Vogel-Claussen J, Ratjen F, Santyr G. Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis. Eur Respir J. 2021 Apr 15;57(4):2003104. doi: 10.1183/13993003.03104-2020. Print 2021 Apr. No abstract available.
PubMed 33303537Kanhere N, Couch MJ, Kowalik K, Zanette B, Rayment JH, Manson D, Subbarao P, Ratjen F, Santyr G. Correlation of Lung Clearance Index with Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. Am J Respir Crit Care Med. 2017 Oct 15;196(8):1073-1075. doi: 10.1164/rccm.201611-2228LE. No abstract available.
PubMed 28245140
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of Hyperpolarized Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease
- ClinicalTrials.gov ID
- NCT02740868
- Acronym / sponsor ID
- 1000048243
- Conditions
- Cystic Fibrosis, Asthma
- Keywords
- Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- The Hospital for Sick ChildrenUniversity, hospital or other
- Study start
- Aug 2015
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 15 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim of this study is to evaluate image quality and reproducibility of Xenon-129 and Inert fluorinated (19F) gas Magnetic Resonance Imaging (MRI) and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.
Detailed description
Hyperpolarized noble gas magnetic resonance (MR) lung imaging is a relatively new imaging method that allows depiction of both lung function and morphology. Hyperpolarized gases are a new class of MR contrast agent which, when inhaled, provide high temporal and spatial resolution MR images of the lung airspaces. Since no ionizing radiation is involved, hyperpolarized gas MR imaging is ideal for the evaluation of lung diseases especially in children. With hyperpolarized gases, the nuclear spins of the gas atoms are brought into alignment outside of the MR scanner via a process called optical pumping; this yields high polarizations and permits visualization of the lung airspaces with MR imaging (despite the low physical density of the gas in the lung). Two non-radioactive (i.e. stable) isotopes of noble gases helium-3 and xenon-129 can be hyperpolarized. Until recently, higher polarizations could be achieved with helium-3 than with xenon-129, so in humans, helium-3 was more commonly used for hyperpolarized gas MR imaging of the lungs. Recently, the technology has been developed to provide large quantities of highly polarized xenon-129. Helium-3 gas is also extremely expensive and since there are limited reserves of the gas, difficult to procure for research. Unlike helium-3, since xenon-129 is naturally present in the atmosphere, it is less expensive and easier to procure for imaging.
Several applications of xenon-129 MR imaging are under development, including diffusion-weighted and relaxation-weighted imaging. These techniques take advantage of the fact that the rate of loss of xenon-129 polarization is significantly influenced by the local blood flow and concentration of molecular oxygen, as well as the restriction of xenon-129 diffusion by small airway space dimensions. These data can be used to create maps of the lung reflecting regional ventilation/perfusion and micro-airway sizes. Other data that can be obtained with xenon-129 MRI include the volumes of ventilated and unventilated lungs which can subsequently be analyzed to determine the homogeneity of gas distribution within the airspaces. These data can be used to study the structural and functional changes taking place in the lungs associated with pulmonary diseases like CF and asthma. It might provide a diagnostic tool that is able to detect pulmonary diseases more sensitively than the current gold standard measurements of spirometry and plethysmography, and thus prevent irreparable and irreversible damage to the lungs in the early stages of disease.
19F MRI is an emergent technology for the imaging of lung ventilation and function. Similar to HP 129Xe MRI, this technique involves the imaging of an inhaled tracer (inert fluorinated gases) to visualize the airspaces of the lungs. Fluorinated gases such as perfluoropropane have been approved for use as an investigational inhaled contrast at several institutions globally, including a Canadian institution in Thunder Bay, Ontario. Fluorinated gases are non-toxic, commercially available, relatively inexpensive, and have favourable physical/magnetic properties for MRI17-20. Most importantly, unlike 129Xe MRI, fluorinated gases do not require hyperpolarization prior to imaging to boost detectable signal, instead relying on a relatively high number of 19F atoms per molecule and rapid, repeated imaging to enable sufficient signal averaging3. This is a significant advantage compared to HP 129Xe MRI which requires special polarizing equipment; a major barrier to widespread implementation. Despite this, the achievable image quality is generally poorer than 129Xe MRI. Nevertheless, recent improvements in hardware, software and fluorinated gases may enable 19F MRI to provide similar and/or complimentary information compared to HP 129Xe MRI at lower cost and with reduced requirements for hardware and infrastructure21.
Additionally, the paramagnetism of molecular oxygen (O2), which detrimentally impacts the hyperpolarization of 129Xe, does not significantly impact inert fluorinated gases. Therefore, these gases may be prepared in normoxic mixtures prior to administration to participants, rather than in anoxic mixtures as is typically done with 129Xe. This, alongside the fact that irreversible loss of magnetization is not a concern with fluorinated gases, presents the opportunity to perform free-breathing, extended imaging of the lungs. Imaging data acquired during free-breathing can potentially resolve gas kinetics (i.e., gas-wash-in, wash-out, and fractional ventilation)22,23 in a manner that is more feasible and tolerable than with HP noble gases.
Due to the lack of studies evaluating 19F MRI in pediatric lung disease, in this study we aim to develop and test necessary hardware/software for 19F MRI of the lungs children with and without history of respiratory disease and compare to HP 129Xe MRI.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy | Active comparator | Drug: Xenon-129 and Perfluoropropane (19F), Device: Magnetic Resonance Imaging, Device: Lung Clearance IndexHealthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index. |
| Cystic Fibrisos | Active comparator | Drug: Xenon-129 and Perfluoropropane (19F), Device: Magnetic Resonance Imaging, Device: Lung Clearance IndexParticipants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index. |
| Asthma | Active comparator | Drug: Xenon-129 and Perfluoropropane (19F), Device: Magnetic Resonance Imaging, Device: Lung Clearance IndexParticipants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index. |
Who may qualify
- Ages
- 8 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- Participants male and female aged 8 years old and older.
- Participants have no smoking history.
- For participants with CF and asthma, a clinical diagnosis is necessary and they should be at their baseline level of symptom control based on history.
- Participants should have a FEV1%pred value greater than 40%.
- Participant understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent or assent.
Key exclusion criteria (9 listed)
- Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent/assent from being obtained, or cannot read or understand the written material.
- Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension.
- Other than for the PEx sub-cohort, participant has had a cold or respiratory infection in the last four weeks.
- Participant requires supplemental oxygen or has a daytime room air oxygen saturation ≤ 95%.
- Participant is unable to perform spirometry or plethysmography maneuvers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Xenon-129 and Perfluoropropane (19F)Also: 129Xe and 19FXenon gas and perfluoropropane to be inhaled by research participants | Drug | Asthma, Cystic Fibrisos, Healthy |
| Magnetic Resonance ImagingAlso: MRILung imaging will be performed for participants using MRI for all 3 arms | Device | Asthma, Cystic Fibrisos, Healthy |
| Lung Clearance IndexAlso: LCILung clearance index (measure of lung health) will be performed for all participants of all 3 arms | Device | Asthma, Cystic Fibrisos, Healthy |
Primary outcome
Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement
Time frame: 1 year
To evaluate image quality and reproducibility of 129Xe and inert fluorinated (19F) gas MRI and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Derived from this study: PubMed 33303537Munidasa S, Couch MJ, Rayment JH, Voskrebenzev A, Seethamraju R, Vogel-Claussen J, Ratjen F, Santyr G. Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis. Eur Respir J. 2021 Apr 15;57(4):2003104. doi: 10.1183/13993003.03104-2020. Print 2021 Apr. No abstract available.
- Derived from this study: PubMed 28245140Kanhere N, Couch MJ, Kowalik K, Zanette B, Rayment JH, Manson D, Subbarao P, Ratjen F, Santyr G. Correlation of Lung Clearance Index with Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. Am J Respir Crit Care Med. 2017 Oct 15;196(8):1073-1075. doi: 10.1164/rccm.201611-2228LE. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Cystic Fibrosis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
Active, not recruiting
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
Cystic Fibrosis (CF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Giles Santyr, PhD principal investigator
The Hospital for Sick Children
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging and Lung Clearance Index in people with Cystic Fibrosis and Asthma, run by The Hospital for Sick Children at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Giles Santyr, PhD (416-813-7654 ext. 301394, giles.santyr@sickkids.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02740868, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.